Stock Analysis

AK Medical Holdings Full Year 2023 Earnings: Misses Expectations

SEHK:1789
Source: Shutterstock

AK Medical Holdings (HKG:1789) Full Year 2023 Results

Key Financial Results

  • Revenue: CN¥1.09b (up 4.0% from FY 2022).
  • Net income: CN¥182.1m (down 11% from FY 2022).
  • Profit margin: 17% (down from 20% in FY 2022). The decrease in margin was driven by higher expenses.
  • EPS: CN¥0.16 (down from CN¥0.18 in FY 2022).
earnings-and-revenue-growth
SEHK:1789 Earnings and Revenue Growth March 28th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

AK Medical Holdings Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 15%. Earnings per share (EPS) also missed analyst estimates by 29%.

Looking ahead, revenue is forecast to grow 30% p.a. on average during the next 2 years, compared to a 23% growth forecast for the Medical Equipment industry in Hong Kong.

Performance of the Hong Kong Medical Equipment industry.

The company's shares are down 6.5% from a week ago.

Balance Sheet Analysis

While it's very important to consider the profit and loss statement, you can also learn a lot about a company by looking at its balance sheet. We have a graphic representation of AK Medical Holdings' balance sheet and an in-depth analysis of the company's financial position.

Valuation is complex, but we're helping make it simple.

Find out whether AK Medical Holdings is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.

View the Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.